Novo Nordisk A/S is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals, primarily in the fields of diabetes care and hormone replacement therapy. With a strong emphasis on research and development, the company aims to improve the lives of patients with chronic conditions by providing high-quality medications and medical devices. Novo Nordisk is recognized for its comprehensive approach to diabetes management, including insulin products and modern delivery systems, while also expanding its portfolio to address other serious conditions, such as obesity and rare blood disorders. The company operates in numerous countries, combining expertise in biotechnology with a commitment to sustainability and corporate responsibility. Read More
The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently, pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) saw their shares plummet following a new round of
Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.
Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks.
Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price.
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
